MRKR

Marker Therapeutics (MRKR) has been upgraded to a Zacks Rank #1 (Strong Buy) rating due to rising earnings estimates. The company's consensus estimate has increased 45.3% over the past three months, positioning it in the top 5% of Zacks-covered stocks. The upgrade reflects an improving business outlook that could drive near-term stock price appreciation.

Marker Therapeutics received a $2.6 million FDA Orphan Products Clinical Trials grant to support Phase 1 clinical studies of MT-601, its multi-antigen recognizing T cell therapy, in locally advanced unresectable pancreatic cancer. The award represents competitive recognition of the company's MAR-T platform, which has shown a disease control rate of 84.6% in earlier studies. Clinical initiation is anticipated in Q1 2027.

Zacks has added five stocks to its Strong Buy list based on increasing consensus earnings estimates over the last 60 days. The stocks span energy, technology distribution, immuno-oncology, biopharmaceutical, and chemical manufacturing sectors, with earnings estimate increases ranging from 3.5% to 30.6%.